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OBJECTIVES: The objective of this workshop is to de-
scribe the approach used in developing a comprehensive,
multi-national breast cancer treatment model. This dis-
ease model was developed for six international markets—
U.S., U.K., Germany, Japan, France, and Italy—and in-
cludes over 70 treatment comparators used in 24 unique
decision trees. The model’s flexibility, with nearly 350
variable cost components related to the diagnosis, treat-
ment, and outcomes of breast cancer, allows for an ex-
amination of the effect of varying cost and probability
scenarios to reflect a multitude of country-specific treat-
ment practices and international practice variations.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved in the development of international clinical
and economic decision analysis models.
A disease treatment model can be a useful tool for com-
prehensively evaluating the clinical and economic aspects
of a specific disease. This workshop will explain the steps
involved in building the model, including: Use of ac-
cepted clinical guidelines to develop treatment pathways
and the use of expert-opinion to reflect variations in ac-
tual current practice Probability data collection for over
144 million decision nodes Cost data collection for all
treatments and cost components. Computer software
used to program the model. Interaction of clinical end-
point, cost, and clinical pathway modules. Type of results
generated (e.g., database queries, sequence queries, cost-
effectiveness analysis). Limitations and possible applica-
tions to other diseases Participants in this workshop will
have an opportunity to suggest customized queries to be
answered by the model.
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OBJECTIVES: Cost-effectiveness analysis requires esti-
mating gains in life expectancy from effective treatments.
Survival is not an endpoint in many clinical trials, be-
cause of limited follow-up intervals or statistical power.
If databases linking survival to the surrogate markers
used in the trials are not available, fragmentary published
data based on follow-up studies may suffice. This work-
shop illustrates methods for using limited published data
to estimate life expectancy gains. Participants will be en-
couraged to share their own experiences in modeling life
expectancy.
PARTICIPANTS WHO WOULD BENEFIT: Analysts
who want to estimate cost-effectiveness based on limited
published data.
This workshop illustrates methods for using limited pub-
lished data to estimate life expectancy gains. The exam-
ple concerns AIDS wasting, in which patients with HIV
infection experience significant weight loss. Treatments
such as human growth hormone (HGH) and anabolic
steroids have been found effective in retarding weight
loss or even restoring body weight in patients with AIDS
wasting. Published survival curves stratified by weight
change from baseline (in ranges such as 10% to 5%)
and CD4 cell count were found in the literature. A clini-
cal trial of HGH reported means and standard deviations
of weight change from baseline with drug and with pla-
cebo. Our task was to use these data to estimate the life
expectancy gain with HGH in patients stratified by CD4
cell count. The presenters will demonstrate the following
analytic steps: (1) estimating probability distributions of
weight change from the clinical trial and using these to
estimate the probability that patients would experience
each range of weight change; (2) estimating areas under
the published survival curves to estimate truncated life
expectancies by range of weight change; (3) using the
DEALE method to extrapolate survival and life expect-
ancy beyond the trial follow-up period; (4) combining
steps (1)-(3) to estimate the gain in life expectancy attrib-
utable to treatment; and (5) applying discounting to the
survival analysis and life expectancy calculations. As with
all life expectancy estimates mediated by surrogate mark-
ers, there is no “proof” that weight change caused by
treatment will translate into life expectancy gains. In the
absence of direct evidence of a survival benefit, however,
these methods can be used to estimate potential life ex-
pectancy gains.
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OBJECTIVES: The objective of this workshop will be to
develop an understanding of conjoint analysis methodol-
ogy, and how it can be used to conduct cost-utility analy-
sis and cost-benefit analysis by capturing patient prefer-
ences.
PARTICIPANTS WHO WOULD BENEFIT: Analysts
involved in the conduct of pharmacoeconomic studies,
particularly those interested in the patient’s perspective.
Cost-utility analysis (CUA) and cost-benefit analysis
(CBA) are alternate analytical frameworks that can be
used to evaluate health interventions. CUA uses a non-
monetary metric, such as quality-adjusted life years
(QALYs), to value health benefits. In CBA, both costs
and benefits are measured in monetary terms. Conjoint
analysis can be used to estimate the benefits of an inter-
vention in either monetary or non-monetary terms and
can be used in both CUA and CBA. In this workshop, we
